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Generalized lipodystrophy is a rare disorder characterized by marked loss of adipose tissueexcess energy,
aThe Cedars-S
Angeles, Californ
Department of I
Medical Center, D
Manuscript receiv
accepted May 10,
Dr. Nelson is
Fellow. This wo
DK54387, M01-R
tutes of Health, B
Dallas, Texas; and
See page 1024
*Correspondin
E-mail addres
0002-9149/13 2
http://dx.doi.org/1with reduced triglyceride storage capacity, leading to a severe form of metabolic syndrome
including hypertriglyceridemia, insulin resistance, type 2 diabetes mellitus, and hepatic
steatosis. Recent echocardiographic studies suggest that concentric left ventricular (LV)
hypertrophy is another characteristic feature of this syndrome, but the mechanism remains
unknown. It has recently been hypothesized that the LV hypertrophy could be an extreme
clinical example of “lipotoxic cardiomyopathy”: excessive myocyte accumulation of
triglyceride leading to adverse hypertrophic signaling. To test this hypothesis, the ﬁrst
cardiac magnetic resonance study of patients with generalized lipodystrophy was per-
formed, using magnetic resonance imaging and localized proton spectroscopy to detect
excessive triglyceride content in the hypertrophied myocytes. Six patients with generalized
lipodystrophy and 6 healthy controls matched for age, gender, and body mass index were
studied. As hypothesized, myocardial triglyceride content was threefold higher in patients
than controls: 0.6 – 0.2% versus 0.2 – 0.1% (p[ 0.004). The presence of pericardial fat was
also found, representing a previously undescribed adipose depot in generalized lipodys-
trophy. Patients with generalized lipodystrophy, compared with controls, also had
a striking degree of concentric LV hypertrophy, independent of blood pressure: LV mass
index 101.0 – 18.3 versus 69.0 – 17.7 g/m2, respectively (p[ 0.02), and LV concentricity 1.3
– 0.3 versus 0.99 – 0.1 g/ml, respectively (p[ 0.04). In conclusion, these ﬁndings advance
the lipotoxicity hypothesis as a putative underlying mechanism for the dramatic concentric
LV hypertrophy found in generalized lipodystrophy. 2013 The Authors. Published byElsevier Inc. (Am J Car
diol 2013;112:1019e1024)
Open access under CC BY license. -Lipodystrophy is an extremely rare disorder character-
ized by loss of body fat and thus deﬁciency of the adipo-
cytokines, such as leptin and adiponectin.1 The cause can be
either inherited or acquired, and the loss of body fat may be
generalized or partial. Patients with generalized lipodys-
trophy are markedly leptin deﬁcient and are severely
hyperphagic, but they have no adipose tissue to store theleading to ectopic deposition of triglyceride
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Open access undein nonadipose tissue, most notably the parenchymal cells
of the liver and skeletal muscle.2,3 Consequently, they
develop a severe form of metabolic syndrome with insulin
resistance, type 2 diabetes mellitus, hypertriglyceridemia,
and nonalcoholic fatty liver disease.4 Recent echocardio-
graphic studies suggest that concentric left ventricular (LV)
hypertrophy constitutes another common feature of patients
with either congenital or acquired generalized lipodys-
trophy.5 Although the precise underlying mechanism
remains unknown, an attractive hypothesis is that the LV
hypertrophy could be an extreme clinical example of “lip-
otoxic cardiomyopathy”: excessive myocyte accumulation
of triglyceride (i.e., “cardiac steatosis”) leading to adverse
hypertrophic signaling. However, myocardial triglyceride
content has not previously been measured in these patients.
We therefore used magnetic resonance imaging (MRI) and
localized proton magnetic resonance spectroscopy (MRS) to
determine if there was a relation between myocardial
hypertrophy and triglyceride content in patients with
generalized lipodystrophy.
Methods
Six patients with generalized lipodystrophy (2 with
congenital generalized lipodystrophy type 1 due to acylgly-
cerol phosphate acyltransferase isoform 2 gene mutations, 3
with type 2 congenital generalized lipodystrophy due towww.ajconline.orgr CC BY license.
Figure 1. (A) Measurement of myocardial triglyceride content by localized hydrogen-1 MRS in a representative patient with lipodystrophy. (Top) Cine
4-chamber and short-axis cardiac image. The volume of interest (voxel) is placed within the interventricular septum (green rectangle). (Bottom) Spectrum from
myocardial tissue collected simultaneously at end-expiration and end-systole with respiratory gating and electrocardiographic triggering, respectively.
(B) Individual cross-sectional comparison of intramyocellular triglyceride content in 6 patients with generalized lipodystrophy compared with 6 controls
matched for age, gender, and body mass index (solid circle, patient 1, pair 1; solid square, patient 2, pair 2; open circle, patient 3, pair 3; open square, patient 4,
pair 4; solid triangle, patient 5, pair 5; open triangle, patient 6; pair 6). (C) Group average cross-sectional comparison of myocardial triglyceride (mTG) content,
demonstrating a threefold difference in myocardial triglyceride content in patients compared with controls. Data are reported as mean  SEM; p <0.05.
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and 1 with acquired generalized lipodystrophy) were
recruited for the present investigation. For cross-sectional
comparison, 6 healthy control subjects, matched for age,
gender, and body mass index, without metabolic disease,
were selected from an existing database. The study was
approved by the Institutional Review Board of the University
of Texas Southwestern Medical Center, and all participants
provided written informed consent before the study.
Body mass index was calculated as weight in kilograms
divided by the square of height in meters. Body surface area
was calculated according to the formula of DuBois andDuBois.6 Blood pressure was measured in the seated posi-
tion, with a validated oscillometric sphygmomanometer
(series 52000; Welch Allyn, Inc., Arden, North Carolina),
with an appropriately sized cuff placed on the upper left
arm. Venous blood samples were obtained from all partic-
ipants and processed according to standard laboratory
procedures.7
All cardiac magnetic resonance experiments were per-
formed using a 1.5-T Gyroscan Intera whole-body magnetic
resonance system (Philips Medical Systems, Best, The
Netherlands). Cardiac MRI was used to assess LV
morphology, as previously described.8,9 Cardiac MRS was
Table 1
Cross-sectional participant characteristics: patients versus controls
Variable Pair 1 Pair 2 Pair 3 Pair 4 Pair 5 Pair 6 Mean  SD p Value
Patient Control Patient Control Patient Control Patient Control Patient Control Patient Control Patient Control
Anthropometrics
Age (yrs) 16 23 18 33 20 19 21 22 23 23 30 27 21  5 24  5 0.288
Gender F F F F M M M M F F F F — —
Height (cm) 160 158 162 160 175 173 163 184 176 160 171 168 168  7 167  0.1 0.941
Weight (kg) 50 51 47 46 83.4 86 66 81 72 55.9 71.3 65.8 64.9  14.0 64.3  16.3 0.897
Body mass index (kg/m2) 19.5 20.4 17.9 18.0 27.2 28.7 24.8 23.9 23.2 21.8 24.4 23.3 22.9  3.5 22.7  3.6 0.944
Body surface area (m2) 1.5 1.5 1.5 1.5 2.0 2.0 1.7 2.0 1.9 1.6 1.8 1.8 1.7  0.2 1.7  0.3 0.924
Hemodynamics
Systolic blood pressure (mm Hg) 120 112 106 118 142 141 125 122 122 106 166 136 130  21 122  14 0.470
Diastolic blood pressure (mm Hg) 76 74 60 69 71 71 78 67 76 63 98 86 77  12 72  8 0.440
Mean arterial pressure (mm Hg) 91 87 75 85 95 94 94 85 91 77 121 102 94  145 89  9 0.427
Heart rate (beats/min) 85 84 80 86 82 67 85 56 75 60 105 78 85  10 69  12 0.038
LV morphology
End-diastolic volume (ml) 120 111.6 103.4 77.7 178.1 141 142.6 169.5 137.9 121.2 127.5 93.6 135.0  25.3 119.1  33.0 0.372
End-systolic volume (ml) 45.3 51.7 33.5 27.2 76.5 53.2 50.6 44.5 56.5 46.5 51.9 27.9 52.4  14.2 41.8  11.5 0.188
Stroke volume (ml) 75.1 60 69.9 50.5 101.6 87.8 92 125.0 81.4 74.7 75.6 65.7 82.6  12.0 77.3  26.6 0.665
Ejection fraction (%) 62 54 67.7 67 57 62 65 73.7 59 61.7 59 70 62  4 65  7 0.372
Mass (g) 147.5 99.5 110.7 65.4 212.0 140.4 196 195 163.4 126.3 229.1 98.6 176.4  44.2 120.9  44.6 0.055
Mass index (g/m2) 98.2 66.3 75.0 45.1 106.5 70.2 114.5 95.6 87 80.3 125.1 56.4 101.0  18.3 69.0  17.7 0.012
Concentricity (g/ml) 1.2 0.9 1.1 0.8 1.2 1.0 1.4 1.2 1.2 1.0 1.8 1.0 1.3  0.3 0.99  0.1 0.023
Blood chemistry
Glucose (mg/dl) 237 89 81 86 303 99 182 90 81 80 105 94 164.8  91.9 89.7  6.5 0.07
Triglycerides (mg/dl) 1,420 123 66.3 72 2,270 193 90 42 663 34 702 82 968.0  765.1 91.0  59.2 0.02
Cholesterol (mg/dl) 291 192 196 167 448 204 129 129 196 137 203 180 243.8  112.6 168.2  30.0 0.143
High-density lipoproteins (mg/dl) 32.4 61.3 27 62 46.0 34.5 28.1 35 27 49.4 26.4 56.7 31.2  7.6 49.8  12.5 0.01
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Figure 2. High-resolution magnetic resonance images. (Top) Cine 4-chamber cardiac magnetic resonance images. Note the presence of pericardial fat in
the patient and the control. The control also has chest wall fat, whereas the patient does not. (Middle) Axial T1-weighted magnetic resonance image of the
calf. Increased typical intensity indicates fat, demonstrating a general lack of adipose tissue in the patient, whereas the control has normal levels of adipose
tissue surrounding skeletal muscle. (Bottom) Axial abdominal magnetic resonance images at the level of the liver. The liver appears bright because of
hepatic steatosis in the patient with lipodystrophy. Note the general lack of subcutaneous and visceral adipose tissue in the patient with generalized
lipodystrophy.
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eride content, as described in detail elsewhere.2,3,10,11
Brieﬂy, image-guided MRS was performed with the
following imaging parameters: repetition time 4 seconds,
echo time 25 ms, and 1,024 data points over a 1,000-kHz
spectral width. The volume of interest (voxel) was centered
over the intraventricular septum at end-systole to avoid
vascular structures and gross adipose tissue deposits and to
ensure consistent orientation of muscle ﬁbers along the
magnetic ﬁeld (Figure 1). Spectra were processed and
resonances quantiﬁed using a standard analysis package
(NUTS; ACORNNMR, Fremont, California). Myocardial
triglyceride content is expressed as a percentage of the
intensity of the water resonance peak.Cross-sectional comparisons (patients vs controls) were
performed using independent-samples Student’s t tests. The
level of signiﬁcance was set a priori at p 0.05. Data are
reported as mean  SE, unless otherwise speciﬁed.
Results
Patient-speciﬁc characteristics are listed in Table 1.
Patients and controls were well matched for age, height, and
weight, and therefore no differences in body surface area or
body mass index were found. As expected, patients had
elevated circulating triglycerides and fasting glucose, with 4
of the 6 patients being treated with insulin (patients from
pairs 1, 3, 4, and 6; Table 1). One patient (pair 6) was being
Figure 3. LV concentricity and LV mass are independent of arterial blood pressure. Note that with the 2 patients with the highest blood pressure removed,
systolic blood pressure (A) decreases to less than that of controls, but LV mass indexed to body surface area (BSA) (B) and LV concentricity (C) remain
elevated above controls. Subject-speciﬁc data are presented (solid circle, patient 1, pair 1; solid square, patient 2, pair 2; open circle, patient 3, pair 3; open
square, patient 4, pair 4; solid triangle, patient 5, pair 5; open triangle, patient 6; pair 6), along with the mean and SE (open bars). *p <0.05.
Miscellaneous/Cardiac Steatosis in Generalized Lipodystrophy 1023treated with a lipid-lowering medication at the time of the
study. No difference in serum cholesterol level was found,
whereas high-density lipoprotein cholesterol was signiﬁ-
cantly lower in patients compared with controls. Blood
pressure was similar between the 2 groups and in the
normotensive range, except for 2 patients with lipodys-
trophy (pairs 3 and 6) whose blood pressures were elevated
at the time of the study.
The major novel ﬁnding of our study is that intra-
myocardial triglyceride content was threefold higher
in patients with lipodystrophy compared with controls
(p ¼ 0.004; Figure 1). Unexpectedly, cardiac MRI also
detected pericardial adipose tissue in the patients, despite
their general lack of adipose tissue elsewhere in the body
(Figure 2). Last, LV mass indexed to body surface area and
LV concentricity were dramatically increased in patients
compared with controls (Table 1), regardless of whether the
2 patients with elevated blood pressure were excluded from
analysis (Figure 3). No group differences were found in LV
end-diastolic volume, end-systolic volume, stroke volume,
or ejection fraction between groups (Table 1).
Discussion
This is the ﬁrst cardiac MRI study of patients with
generalized lipodystrophy. The MRI data conﬁrm a high
degree of concentric LV hypertrophy, as suggested by
previous echocardiographic studies, and document 2 major
new ﬁndings. First, consistent with the lipotoxicity
hypothesis, we found that myocardial triglyceride content
was markedly elevated in the patients’ hypertrophied car-
diomyocytes. Second, we unexpectedly found pericardial fat
to be present in all the patients, representing a previously
undescribed depot of adipocytes preserved in generalized
lipodystrophy.
Generalized lipodystrophy has been associated with
ectopic accumulation of triglyceride in the parenchymal
cells of the liver and skeletal muscle.2,3 The threefold
elevation in myocardial triglyceride content in our patients
shows that the heart is another steatotic target organ in this
disease. From a mechanistic standpoint, generalized lip-
odystrophy is a perfect storm for cardiac steatosis. In
patients with congenital generalized lipodystrophy, wide-
spread failure of adipogenesis causes leptin deﬁciency and
a greatly reduced adipocyte pool to store triglyceride. Inpatients with acquired generalized lipodystrophy, autoim-
mune or other unknown mechanisms cause loss of adipose
tissue. These patients therefore lack the central neural action
of leptin, which suppresses appetite, and the peripheral
antisteatotic action of leptin, which upregulates fatty acid
oxidation of nonadipose tissue, so as to oxidize any lipid
spillover that may have occurred because of overnutrition.12
Furthermore, secondary insulin resistance would also be
expected to disrupt the balance of cardiac substrate utiliza-
tion, favoring greater uptake of fatty acids.13,14
In addition to the new spectroscopy data, our imaging data
not only conﬁrm a dramatic degree of concentric LV hyper-
trophy in generalized lipodystrophy but also document the
consistent presence of pericardial fat. The latter ﬁnding was
quite unexpected because pericardial fat represents a pro-
tected pool of adipocytes in a disease characterized by
widespread failure of adipogenesis. This in vivo cardiac MRI
ﬁnding differs from autopsy studies concluding that patients
with generalized lipodystrophy have no pericardial fat.15,16
We interpret our data to suggest that the beating heart
produces repetitive stimulation of mechanosensitive tran-
scriptional elements of genes involved in adipogenesis.
Mechanosensitive adipogenesis is indeed an accepted expla-
nation for the residual adipose tissue patients with congenital
generalized lipodystrophy type 1 have in the intraorbital
region, palms, and soles.17 Thus, although generalized lip-
odystrophy results in poor growth and development of
metabolically active adipose tissue, “mechanical adipose
tissue” (reducing friction) appears preserved with pericardial
fat, constituting yet another example.
The major strength of this study is the application of
cardiac MRI and MRS in an extremely rare human disease
that provides a unique experiment of nature to study cardiac
lipotoxicity in the absence of generalized obesity. Although
these data in patients with generalized lipodystrophy are
entirely consistent with the concentric LV hypertrophy being
an extreme human example of lipotoxic cardiomyopathy, the
major limitation of this work is that these cross-sectional data
cannot prove causal attribution. Importantly, our patients’LV
hypertrophy appears to have been independent of hyperten-
sion and thus was not pressure overload hypertrophy. Like-
wise, none of the patients was actively engaged in regular
exercise training, excluding the possibility of exercise-
induced cardiac remodeling. We also did not observe
1024 The American Journal of Cardiology (www.ajconline.org)a systematic relation between those with impaired glucose
tolerance, who were receiving insulin injections, and
the development of LV hypertrophy, suggesting that the
hypertrophy observed in our patients may have been inde-
pendent of insulin. Last, pericardial fat has recently been
implicated in the pathogenesis of LV hypertrophy,18e20 but
the amount of pericardial fat in our patients appeared no
higher than normal. Thus, it is tempting to speculate that the
development of LV hypertrophy in patients with generalized
lipodystrophy is mechanistically linked to their dramatic
cardiac steatosis. Indeed, in transgenic mouse models,
cardiac-speciﬁc overexpression of fatty acid transport
proteins, or enzymes involved in triglyceride synthesis,
produces severe cardiac steatosis, with the excess fatty acid
causing concentric LV hypertrophy.21,22 Thus, in addition to
providing a potential mechanistic explanation for the well-
described cardiomegaly described in generalized lipodys-
trophy, the present results may also provide important insight
into the development of obesity related cardiomyopathy.
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